MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek; Chih Cheng Chen; Miklós Egyed; Martin Ellis; Laura Fox; Yeow T. Goh; Vikas Gupta; Claire Harrison; Jean Jacques Kiladjian; Mihaela C. Lazaroiu; Adam Mead; Donal McLornan; Mary F. McMullin; Stephen T. Oh; Andrew Perkins; Uwe Platzbecker; Christof Scheid; Alessandro Vannucchi; Sung Soo Yoon; Mark M. Kowalski; Ruben A. Mesa

doi:10.2217/fon-2020-1048

MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T. Goh, Vikas Gupta, Claire Harrison, Jean Jacques Kiladjian, Mihaela C. Lazaroiu, Adam Mead, Donal McLornan, Mary F. McMullin, Stephen T. Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung Soo Yoon, Mark M. Kowalski^*Ruben A. Mesa

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Original language	English
Pages (from-to)	1449-1458
Number of pages	10
Journal	Future Oncology
Volume	17
Issue number	12
DOIs	https://doi.org/10.2217/fon-2020-1048
State	Published - Apr 2021

Funding

Funders	Funder number
Blueprint Medicines Corp.
NS Pharma
Intel Corporation
AMGEN
Genentech
Merck
Novartis
Roche
Gilead Sciences
Janssen Biotech
Celgene
Sierra Oncology

Keywords

ACVR1
JAK inhibitor
Phase III clinical trial
anemia
danazol
hemoglobin
momelotinib
myelofibrosis
transfusion

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2020-1048

Cite this

Verstovsek, S., Chen, C. C., Egyed, M., Ellis, M., Fox, L., Goh, Y. T., Gupta, V., Harrison, C., Kiladjian, J. J., Lazaroiu, M. C., Mead, A., McLornan, D., McMullin, M. F., Oh, S. T., Perkins, A., Platzbecker, U., Scheid, C., Vannucchi, A., Yoon, S. S., ... Mesa, R. A. (2021). MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 17(12), 1449-1458. https://doi.org/10.2217/fon-2020-1048

@article{1be3bd99ee6a4b8f8a028a4f8f1a32b1,

title = "MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic",

abstract = "Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.",

keywords = "ACVR1, JAK inhibitor, Phase III clinical trial, anemia, danazol, hemoglobin, momelotinib, myelofibrosis, transfusion",

author = "Srdan Verstovsek and Chen, {Chih Cheng} and Mikl{\'o}s Egyed and Martin Ellis and Laura Fox and Goh, {Yeow T.} and Vikas Gupta and Claire Harrison and Kiladjian, {Jean Jacques} and Lazaroiu, {Mihaela C.} and Adam Mead and Donal McLornan and McMullin, {Mary F.} and Oh, {Stephen T.} and Andrew Perkins and Uwe Platzbecker and Christof Scheid and Alessandro Vannucchi and Yoon, {Sung Soo} and Kowalski, {Mark M.} and Mesa, {Ruben A.}",

year = "2021",

month = apr,

doi = "10.2217/fon-2020-1048",

language = "אנגלית",

volume = "17",

pages = "1449--1458",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "12",

}

Verstovsek, S, Chen, CC, Egyed, M, Ellis, M, Fox, L, Goh, YT, Gupta, V, Harrison, C, Kiladjian, JJ, Lazaroiu, MC, Mead, A, McLornan, D, McMullin, MF, Oh, ST, Perkins, A, Platzbecker, U, Scheid, C, Vannucchi, A, Yoon, SS, Kowalski, MM & Mesa, RA 2021, 'MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic', Future Oncology, vol. 17, no. 12, pp. 1449-1458. https://doi.org/10.2217/fon-2020-1048

TY - JOUR

T1 - MOMENTUM

T2 - Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

AU - Verstovsek, Srdan

AU - Chen, Chih Cheng

AU - Egyed, Miklós

AU - Ellis, Martin

AU - Fox, Laura

AU - Goh, Yeow T.

AU - Gupta, Vikas

AU - Harrison, Claire

AU - Kiladjian, Jean Jacques

AU - Lazaroiu, Mihaela C.

AU - Mead, Adam

AU - McLornan, Donal

AU - McMullin, Mary F.

AU - Oh, Stephen T.

AU - Perkins, Andrew

AU - Platzbecker, Uwe

AU - Scheid, Christof

AU - Vannucchi, Alessandro

AU - Yoon, Sung Soo

AU - Kowalski, Mark M.

AU - Mesa, Ruben A.

PY - 2021/4

Y1 - 2021/4

N2 - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

AB - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

KW - ACVR1

KW - JAK inhibitor

KW - Phase III clinical trial

KW - anemia

KW - danazol

KW - hemoglobin

KW - momelotinib

KW - myelofibrosis

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85103060890&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-1048

DO - 10.2217/fon-2020-1048

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 33423550

AN - SCOPUS:85103060890

SN - 1479-6694

VL - 17

SP - 1449

EP - 1458

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this